$99.72 +0.87 (0.88%)
Abivax SA American Depositary Shares (ABVX)
Company News
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax reported positive Phase 3 trial results for obefazimod in treating ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate at Week 8 and no significant safety concerns.
2 Beaten-Down Stocks With Incredible Upside Potential
The article explores two promising biotech companies, Viking Therapeutics and Recursion Pharmaceuticals, highlighting their innovative approaches in weight loss treatments and AI-driven drug development, respectively.
Abivax: Why Did ABVX Surge Over 400% in Premarket Trading?
French biotechnology company Abivax SA reported positive Phase 3 clinical trial results for obefazimod, a treatment for ulcerative colitis, causing its stock to surge over 400% in premarket trading on July 23, 2025.